- Δεν υπάρχουν δεδομένα
Ελληνικά
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
Recently, exail (formerly iXblue) announced the acquisition of Leukos, an optical company specializing in providing advanced laser sources for metrology, spectroscopy, and imaging applications.Leukos was founded by the French XLIM Institute (a joint research department of the French National Academy of Sciences and the University of Limoges), with over 20 years of professional experience in the re...
The University of California, Los Angeles is joining LaserNetUS, a high-power laser facility alliance established by the Department of Energy, aimed at advancing laser plasma science.Unique facilities are located in universities and national laboratories across the United States and Canada, providing a wide range of opportunities for researchers and students.The Phoenix Laser Laboratory at the Uni...
Recently, additive manufacturing research company AM Research released its latest quarterly data and forecast report, which deeply analyzes the latest developments in the global 3D printing market, covering multidimensional analysis of suppliers, printing technology, geographic location, and application areas.According to the report, the global 3D printing market once again demonstrates strong gro...
Scientists from the Hanover Laser Center (LZH) in Germany are studying two laser based processes for producing load adapted hybrid solid components.From a transaction perspective, mixing semi-finished products can help save materials and production costs, but if the components that need to be replaced are made of expensive materials, these materials need to meet high requirements in future use, su...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...